Yuhan And Shandong Luoxin Pharmaceutical Group Stock Co., Ltd. Enter Into Exclusive License And Co-Development Agreement For 3rd -Generation EGFR-Targeted Therapy In China
Superior Efficacy and Selectivity of Novel Small-Molecule Kinase Inhibitors of T790M-Mutant EGFR in Preclinical Models of Lung Cancer
This article was published on Cancer Research - AACR Journals, doi: 10.1158/0008-5472.CAN-16-2432 in February 2017.
YH25448, a highly selective 3rd generation EGFR TKI, exhibits superior survival benefit over osimertinib in mice with brain metastases of NSCLC
Genosco's pipeline GNS-1480 (Yuhan code: YH25448) was presented at the IASLC 17th World Conference on Lung Cancer in December 2016. *IASLC stands for International Association for the Study of Lung Cancer.
Crystal structures of spleen tyrosine kinase in complex with novel inhibitors: structural insights for design of anticancer drugs
This article was published in The FEBS Journal, Volume 238, Issue 19, Pages 3613-3625 in October 2016.
This article was published in Bioorganic & Medicinal Chemistry Letters, Volume 25, Issue 20, Pages 4441-4446 in October 2015. It was also featured in World Biomedical Frontiers.
G-749, a novel FLT3 kinase inhibitor, can overcome drug resistance for the treatment of acute myeloid leukemia
This article was published in Blood, Volume 123, Number 14, Pages 2209-2219 in April 2014. It was also published in SciBX, Volume 7, Number 12 in March 2014.
Crystal Structure of Pim1 Kinase in Complex with a Pyrido[4,3-D]Pyrimidine Derivative Suggests a Unique Binding Mode
This article was published on PLoS ONE 8(7): e70358. doi: 10.1371/journal.pone.0070358 in July 2013.